tbuckley/cabot-search huggingface dataset:
Abstract 3665: Aggf1 Is Essential for Embryonic and Pathological Angiogenesis
Authors: Teng Zhang, Ping He, Qing Wang
Journal: Circulation (2008)

Backgroud: AGGF1 is a newly identified angiogenic factor associated with vascular disease Klippel-Trenaunay syndrome. AGGF1 has been shown to promote angiogenesis as potently as VEGF in a chicken embryo angiogenesis assay; however, the physiological role of AGGF1 is unknown. Methods and Results: We explored the physiological function of AGGF1 in vivo by employing the gene-trapping strategy in mice. AGGF1−/− mice died by E8.5, suggesting that AGGF1 is essential for embryogenesis. AGGF1 heterozygosity resulted in 31% embryonic lethality. Further macroscopic analysis of embryos at different stages revealed growth retardation and defective vascular development in AGGF1+/− embryos. The major vascular phenotypes included failed development of large vessels and interconnected yolk sac vasculature. Interestingly, decreased phosphorylation of VEGFR2 (Tyr951) was detected in AGGF1+/− embryos compared to the wild type littermate controls, suggesting that AGGF1 may function through VEGFR2-mediated signaling during angiogenesis. Moreover, vascular pathologies of various internal organs were detected in older AGGF1+/− mice. Hemorrhages were frequently noted in brain, spleen and lung, and a chronic inflammatory change was readily detected in lungs in AGGF1+/− mice compared to the littermate controls. Permeability assay further revealed increased vascular permeability in old AGGF1+/− mice (50 – 60 weeks) compared to age- and sex-matched wild-type controls. A tumor angiogenesis model induced by two melanoma cell lines was employed to further assess the angiogenic function of AGGF1 in vivo. Tumor growth was significantly inhibited in AGGF1+/− mice. Histological examinations of the tumor sections revealed markedly reduced microvessel formation in tumors grown in AGGF1+/− mice. Moreover, vascular density quantified after PECAM1 immunostaining showed significant reduction in tumors grown in AGGF1+/− mice. Conclusions: AGGF1 is an important regulator for embryonic angiogenesis and vascular integrity. AGGF1 is also involved in tumor growth and pathological angiogenesis. These results provide for the first time the in vivo experimental evidence that AGGF1 is a potent angiogenic factor essential for both embryonic and pathological angiogenesis.
Effect of Florida’s Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use
Authors: Lainie Rutkow, Hsien-Yen Chang, Matthew Daubresse, Daniel W. Webster, Elizabeth A. Stuart, G. Caleb Alexander
Journal: JAMA Internal Medicine (2015)

Prescription Drug Monitoring Program (PDMP) and pill mill laws are among the principal means states use to reduce prescription drug abuse and diversion, yet little high-quality evidence exists regarding their effect.OBJECTIVE To quantify the effect of Florida's PDMP and pill mill laws on overall and high-risk opioid prescribing and use. DESIGN, SETTING, AND PARTICIPANTSWe applied comparative interrupted time-series analyses to IMS Health LifeLink LRx data to characterize the effect of PDMP and pill mill law implementation on a closed cohort of prescribers, retail pharmacies, and patients from July 2010 through September 2012 in Florida (intervention state) compared with Georgia (control state).We conducted sensitivity analyses, including varying length of observation and modifying requirements for continuous observation of individuals throughout the study period.MAIN OUTCOMES AND MEASURES Total opioid volume, mean morphine milligram equivalent (MME) per transaction, mean days' supply per transaction, and total number of opioid prescriptions dispensed.Analyses were conducted per prescriber and per patient, in aggregate and after stratifying by volume of baseline opioid prescribing for prescribers and use for patients. RESULTSFrom July 2010 through September 2012, a cohort of 2.6 million patients, 431 890 prescribers, and 2829 pharmacies was associated with approximately 480 million prescriptions in Florida and Georgia, 7.7% of which were for opioids.Total monthly opioid volume, MME per transaction, days' supply, and prescriptions dispensed were higher in Florida than Georgia before implementation.Florida's laws were associated with statistically significant declines in opioid volume (2.5 kg/mo, P < .05;equivalent to approximately 500 000 5-mg tablets of hydrocodone bitartrate per month) and MME per transaction (0.45 mg/mo, P < .05),without any change in days' supply.Twelve months after implementation, the policies were associated with approximately a 1.4% decrease in opioid prescriptions, 2.5% decrease in opioid volume, and 5.6% decrease in MME per transaction.Reductions were limited to prescribers and patients with the highest baseline opioid prescribing and use.Sensitivity analyses, varying time windows, and enrollment criteria supported the main results.CONCLUSIONS AND RELEVANCE Florida's PDMP and pill mill laws were associated with modest decreases in opioid prescribing and use.Decreases were greatest among prescribers and patients with the highest baseline opioid prescribing and use.
Prevalence of Anal Dysplasia in Patients With Inflammatory Bowel Disease
Authors: Shamita B. Shah, Danielle Pickham, Hiwot Araya, Ahmad Kamal, Carlos E. Pineda, Saif Ghole, Lauren Shih, Christina Kong, Reet Pai, Mark Welton
Journal: Clinical Gastroenterology and Hepatology (2015)

Although the prevalence of anal dysplasia is higher in some immunosuppressed populations, the prevalence in patients with inflammatory bowel disease (IBD) is unknown. We examined the prevalence of abnormal anal cytology among IBD patients, and its relation to the human papilloma virus (HPV).Adults with IBD and age-matched healthy controls (HC) were recruited. IBD patients were categorized as nonimmunosuppressed (IBD-N) or immunosuppressed (IBD-I). Anal Papanicolaou tests were performed for HPV testing and classification by a cytopathologist as follows: negative, atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion, high-grade squamous intraepithelial lesion, cancer, or unsatisfactory.A total of 270 subjects (100 IBD-I, 94 IBD-N, and 76 HC) were recruited. ASC-US were detected in 19 subjects, with a trend toward a higher prevalence among IBD subjects compared with HC (8.8% vs 2.6%; P = .10). The prevalence did not differ with respect to immunosuppression. Crohn's disease (CD) subjects had a higher prevalence of ASC-US compared with others with IBD (P = .02). Among those with CD, female sex and disease duration longer than 10 years were risk factors. There were no cases of low-grade squamous intraepithelial lesion, high-grade squamous intraepithelial lesion, or anal cancer in the cohort. HPV was present in 5.3% and 1.5% of subjects with and without ASC-US, respectively (P = .26).Although there was a trend toward abnormal anal Papanicolaou tests in IBD subjects compared with HC, there was no difference based on immunosuppression. The presence of HPV did not correlate with abnormal anal cytology. Risk factors associated with this increased trend include female CD subjects and those with a longer duration of CD. ClinicalTrials.gov number: NCT01860963; https://clinicaltrials.gov/ct2/show/NCT01860963.
Panel Reviews Health Effects Data for Assisted Reproductive Technologies
Authors: Tracy Hampton
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study
Authors: Anna Turkova, Elizabeth Chappell, Ali Judd, Ruth L Goodall, Steven B Welch, Caroline Foster, Andrew Riordan, Delane Shingadia, Fiona Shackley, Katja Doerholt, Diana M Gibb, Intira J Collins
Journal: The Lancet HIV (2015)
Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission—a randomized trial
Authors: K.B. Kristoffersen, O.S. Søgaard, C. Wejse, F.T. Black, T. Greve, B. Tarp, M. Storgaard, M. Sodemann
Journal: Clinical Microbiology and Infection (2009)
Familial Association between Coeliac Disease and Ulcerative Colitis: Preliminary Communication
Authors: J F Mayberry, H L Smart, P J Toghill
Journal: Journal of the Royal Society of Medicine (1986)

One hundred and twenty patients who were members of the Nottinghamshire Coeliac Group completed a questionnaire about the occurrence of coeliac disease, ulcerative colitis and Crohn's disease amongst first-degree relatives. Siblings were at a 20-fold risk of developing coeliac disease and a 15-fold risk of developing ulcerative colitis, and significantly increased risks for these two conditions were also seen in other family members. The relatives of patients with coeliac disease are at increased risk not only of developing coeliac disease but also ulcerative colitis. This provides further support for a possible role of a dietary allergen in the development of ulcerative colitis.
Response to Letter Regarding Article, “Rates of and Factors Associated With Infection in 200 909 Medicare Implantable Cardioverter-Defibrillator Implants: Results From the National Cardiovascular Data Registry”
Authors: Jordan M. Prutkin, Matthew R. Reynolds, Haikun Bao, Jeptha P. Curtis, Sana M. Al-Khatib, Saurabh Aggarwal, Daniel Z. Uslan
Journal: Circulation (2015)
Malady of Recognize
Authors: Marcia Pelletiere
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Accelerated Plasmacytoma Formation in Mice Treated With Alpha-Fetoprotein&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;3&lt;/xref&gt;
Authors: M. Eric Gershwin, James J. Castles, Ronald Makishima
Journal: JNCI Journal of the National Cancer Institute (1980)

The ability of alpha-fetoprotein (AFP), derived from mouse amniotic fluid, to alter qualitative and quantitative characteristics of pristane-induced plasmacytomas and the carcinogenic action of 3-methylcholanthrene (MCA) and 7,12-dimethylbenz]a[-anthracene (DMBA) was studied and compared to analogous treatment with murine albumin and transferrin in BALB/c mice. Pharmacologic doses of 200 microgram AFP ip three times per week had no effect on either latency period or tumor incidence in mice given injections of MCA and DMBA when compared to albumin-treated and transferrin-treated controls. Moreover, this lack of influence of AFP was found at high and low dosages of the carcinogens. In contrast AFP, but neither albumin nor transferrin, accelerated the appearance of plasmacytomas in pristane-primed BALB/c mice. Moreover, the immunoglobulin class of plasmacytomas of mice given AFP injections was qualitatively altered, and in increase in IgM and IgG2b plasmacytomas was noted. These effects occurred at serum AFP levels of 90--260 microgram/ml. Although these results should not be used to support a normal physiologic role of AFP in immune regulation, they are similar to previous observations of suppression mediated by the alpha-globulin fraction of normal serum and suggest that pharmacologic dosages of AFP may be useful in the study of select, possibly thymus-dependent, immune responses.
Correlation of levels of N-terminal pro-B-type natriuretic peptide with localization of thrombus in acute pulmonary embolism
Authors: Evrim Eylem Akpinar, Esen Sayin, Esra Buyuk, Meral Gulhan
Journal: European Respiratory Journal (2011)

Aim:  Brain-natriuretic peptide (BNP) is a hormone which is released from heart.The aim of the study was to investigate whether N- terminal- pro- BNP (pro-BNP) could predict localization of thrombus in patients with acute pulmonary embolism.   Method:  The patients who were evaluated in emergency department, who had thrombus on helical computed tomography were enrolled. Thrombi which were localized on main/right-left pulmonary artery were classified as central,ones which were present at segmentary/subsegmentary levels as peripheral. Echocardiogram was performed and pro-BNP levels were measured.   Results:  Fourty-nine patients were enrolled to the study. The thrombi of 63.3% patients were unilaterally located, of 36.7% bilaterally, 18.4% of patients had thrombi that were central, 81.6% patients had peripheral. The difference between pro-BNP levels of who had central and peripheral thrombus was significant (p=0.039).  Pro-BNP levels of patients who had right ventricule overload (pulmonary HT, septal hypochinesia, dilatation on right heart) were higher (p   Conclusion:  Higher pro-BNP levels indicates higher probability of more central location of thrombus, resulting adverse clinical course and having right ventricular overload.
Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group.
Authors: A P Venook, A Tseng, F J Meyers, I Silverberg, R Boles, K K Fu, C D Jacobs
Journal: Journal of Clinical Oncology (1987)

Seventeen patients with advanced or recurrent salivary gland cancer were treated with cisplatin, doxorubicin, and 5-fluorouracil combination chemotherapy (PAF). Two patients achieved a complete response and four patients achieved a partial response, for an overall response rate of 35%. Six of the nine patients who received PAF in the neoadjuvant setting did not respond and proceeded to surgery and/or radiation therapy. No difference in response rate was found between those patients treated for recurrent disease v those treated with neoadjuvant chemotherapy. All three patients with adenocarcinoma responded. The response duration in patients with metastatic or recurrent disease ranged from 6 to 15 months. The PAF regimen was delivered primarily in the outpatient setting and was associated with acceptable toxicity. PAF demonstrates activity in salivary gland malignancies, and further evaluation of this combination seems warranted.
On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy
Authors: Samia Mora, Robert J. Glynn, S. Matthijs Boekholdt, Børge G. Nordestgaard, John J.P. Kastelein, Paul M. Ridker
Journal: Journal of the American College of Cardiology (2012)
Mosquito Reduction and Malarial Prevention. A Précis.
Authors: John Andrew Crawford, B. S. Chalam
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast cancer
Authors: S. E. Come, L. M. Parker, G. Wulf, I. Kuter, P. D. Ryan, K. Tkaczuk, V. Borges, H. Kasper, R. Gelman, E. P. Winer
Journal: Journal of Clinical Oncology (2009)

1050 Background: At the approved dosage (AD) of 250 mg q 28d, fulvestrant has no dose-limiting toxicity and may not optimally inhibit/downregulate levels of ER. We evaluated the tolerability, efficacy, and pharmacokinetics of fulvestrant given at twice the AD. Methods: 35 postmenopausal patients with ER+ evaluable metastatic breast cancer who had not received endocrine therapy for advanced disease and were at least 12 months from the completion of any adjuvant endocrine therapy were enrolled in a single stage, phase II study. The median age was 64. 15 patients had received prior adjuvant endocrine treatment. 14 had visceral metastases. Treatment consisted of fulvestrant 500 mg (2 x 5 mL injections) on days 1, 15, 29, and q 28d thereafter. Toxicity and response were assessed q 28d by history, exam, and laboratory testing, and q 3 months by imaging. The primary endpoint was clinical benefit rate (CBR) defined as complete responses (CR) plus partial responses (PR) plus stable disease (SD) for &gt; 6 months. This trial was powered to detect a 20% improvement in the 57% CBR reported for AD fulvestrant in the first-line metastatic setting (J Clin Oncol. 2004;22:1605–613). Results: Median time on study is 13 months (mo). 17 patients remain on treatment (8+ to 54+ mo). There has been no grade (gr) 3 or 4 treatment-related toxicity. Transient injection site discomfort or pruritis occurred in 13 patients (11 gr 1, 2 gr 2). A CBR of 86% was observed (95% CI 70%- 95%). The median time to progression is 22 mo. In the subset of 24 patients fulfilling RECIST criteria, 1 CR and 6 PR, and 15 SD were observed (overall response rate 29%, CBR 92%). Conclusions: Doubling the AD of fulvestrant does not increase toxicity. Monthly bilateral 5 mL injections are well tolerated. Importantly, the CBR is improved at this dose and schedule compared to the AD. [Table: see text]
Primary Hepatocellular Carcinoma in Intertropical Africa: Relationship Between Age and Hepatitis B Virus Etiology2
Authors: Pierre Coursaget, Philippe Maupas, Alain Goudeau, Jean-Paul Chiron, Jacques Drucker, François Denis, Iba Diop-Mar
Journal: JNCI Journal of the National Cancer Institute (1980)

Clinical observations of patients with primary hepatocellular carcinoma (PHC) at Le Dantec Hospital, Dakar, Senegal, were studied to determine a correlation with hepatitis B virus (HBV) infection. Of the 103 patients with PHC, 80 had an active HBV infection (HBsAg and/or anti-HBc); 23 showed signs of previous HBV infection (anti-HBs and anti-HBc). The two groups were similar in the detection of α-fetoprotein (≈60%) and in the major clinical findings: hepatomegaly, 76.25% and 86.96%, respectively; and ascites, 57.50% and 47.83%, respectively. Jaundice, however, was three times more frequent (P<0.01) in the group of patients with signs of active HBV replication. Distribution of HBV markers as a function of age at onset of PHC revealed that the presence of HBsAg was primarily confined to the sera of the younger patients (<50 yr old). When compared with leprosy patients and blood donors, the younger PHC patients differed in the frequency of detection of HBsAg and anti-HBs. The older people (>50 yr old) in the three groups (PHC patients, leprosy patients, and blood donors) had identical HBV markers.
Radiologic Atlas of Pulmonary Abnormalities in Children
Journal: Thorax (1989)

We have read with interest the comments of Drs Gianotti and Franconieri.Their observation of a difference in expiratory time during sleep between subjects with intrinsic and extrinsic asthma is interesting but difficult to evaluate.Specifically, it is not clear whether there is a difference in the extent of nocturnal bronchoconstriction between their subjects with intrinsic and extrinsic asthma.As wheeze tends to be associated with prolonged expiration, one would imagine that the longer expiratory time in the patients with intrinsic asthma might have been associated with nocturnal bronchoconstriction.Paragraph 2, however, suggests that the patients with allergic asthma had nocturnal bronchoconstriction but those with intrinsic asthma did not.This requires clarification.Our own data are not directly comparable with the data of Drs Gianotti and Franconieri, as we did not split our patients into those with intrinsic and extrinsic asthma.Indeed, most had intrinsic asthma.We believe that our study adequately shows that there are no changes in breathing pattern overnight which are diagnos- tic of the development of nocturnal bronchoconstriction.We look forward to reading further details of the study of Drs Gianotti and Franconieri in due course.